IMVT (Immunovant) FCF Margin %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMVT Immunovant Inc IMVT
29 GF Score
Price $42.11
! 3 Warning Signs
View Full Analysis

What is Immunovant FCF Margin %?

Immunovant IMVT -1.15% 29 FCF Margin % is 0.00% as of Jun. 2026. GuruFocus rates IMVT with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 954 Biotechnology companies, Immunovant ranks worse than 104821.7% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Immunovant's Free Cash Flow for the three months ended in Jun. 2026 was $-124.41 Mil. Immunovant's Revenue for the three months ended in Jun. 2026 was $0.00 Mil. Therefore, Immunovant's FCF Margin % for the quarter that ended in Jun. 2026 was 0.00%.

As of today, Immunovant's current FCF Yield % is -4.76%.

The historical rank and industry rank for Immunovant's FCF Margin % or its related term are showing as below:


IMVT's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -77.885
* Ranked among companies with meaningful FCF Margin % only.

Immunovant FCF Margin % Related Terms

Immunovant FCF Margin % Historical Data

* Premium members only.

The historical data trend for Immunovant's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovant FCF Margin % Chart

Immunovant Annual Data
Trend Dec18 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Immunovant Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IMVT vs PCVX, TGTX, PTGX: FCF Margin % Comparison

For the Biotechnology subindustry, Immunovant's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunovant FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunovant's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Immunovant's FCF Margin % falls into.


IMVT
29GF Score
Immunovant Inc IMVT
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunovant FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Immunovant's FCF Margin for the fiscal year that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-407.318/0
= %

Immunovant's FCF Margin for the quarter that ended in Jun. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-124.405/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Immunovant (IMVT) has a FCF Margin % of 0.00% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Immunovant and its competitors. According to the industry distribution chart, Immunovant ranks #999999 out of 954 companies in the Biotechnology industry.
Is Immunovant's FCF Margin % too high?
Immunovant's current FCF Margin % is 0.00%. Based on the distribution chart, Immunovant ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunovant has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Immunovant's FCF Margin % compare to PCVX and TGTX?
According to the Biotechnology industry distribution chart, Immunovant ranks #999999 out of 954 companies for FCF Margin %. This places Immunovant in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Immunovant and its competitors. Immunovant's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovant stock overvalued right now?
Immunovant (IMVT) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Immunovant's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Immunovant (IMVT), the current FCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunovant Business Description

Address 1000 Park Forty Plaza, New York, NC, USA, 27713
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
29GF Score

Get the complete analysis for IMVT

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.11
Price